TP53 and non-small cell lung carcinoma: Hence, the impacts of FOSB on the malignant biological behaviors and cisplatin sensitivity in tumor cells might be primarily attributable to the transcriptional activation of its specific transcriptional targets AKR1C3 and ALDH3A1 in NSCLC with the genetic background of TP53-R248Q (Figs. 5 and 6).